CMC and regulatory due diligence for a medical imaging agent

Challenge One of the leading medical imaging companies worldwide approached Alacrita to assess an opportunity to acquire the manufacturing and distribution rights to an important imaging agent used...
Learn More

Technical and market risk assessment for a private equity firm

Challenge Our client, a UK-based private equity company, was evaluating an investment in a full service global medical communications agency with a portfolio of blue-chip biopharma clients, and as...
Learn More

Due diligence, valuation, and licensing of an infectious disease asset

Challenge: A former venture fund client identified a novel Phase 1-ready asset for treating a rare CNS infectious disease and was interested in licensing the asset and founding a new company to...
Learn More

Assessing the clinical development & regulatory pathway for a Phase 3 gene therapy product

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...
Learn More

Clinical due diligence on a company targeting CNS indications

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...
Learn More

KOL & payer market research for small molecule in aortic valve stenosis

Challenge A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was...
Learn More

Providing due diligence in inflammation and fibrosis area

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...
Learn More

Investor due diligence for a live biotherapeutic product

Challenge: A developer of live biotherapeutic products (LBP) derived from stool donations had a lead product in phase 2 clinical trials for metabolic pathology secondary to hepatic pathology. An...
Learn More

Due diligence on a computational chemistry software for a private equity firm

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...
Learn More

Due diligence on a series of investments in oncology and genetic diseases

Challenge: A European investor required due diligence support to appraise the attractiveness of a series of potential investments. The technologies included a theranostic agent, a DNA damage response...
Learn More

Clinical and regulatory due diligence of an asset targeting pre-term birth complications

Challenge: Our client was a European mid-size pharmaceutical company considering an investment in a clinical-stage company developing an asset for multiple indications associated with pre-term birth...
Learn More

Due Diligence on DNA damage response assets

Challenge: An oncology company with a ‘hub and spoke’ structure wished to commission an expert third-party due diligence on one of its spin-out companies in support of its next investment round. The...
Learn More
1 2 3 4 5 ... 9